Sector News

Pfizer vet Gutiérrez-Ramos takes the reins at Synlogic

May 21, 2015
Life sciences
José-Carlos Gutiérrez-Ramos, long Pfizer’s chief of biotherapeutic research, is heading back to the world of biotech, taking the top spot at Synlogic as the startup pursues a novel approach to drug development.
 
Gutiérrez-Ramos, who left Pfizer earlier this month, is stepping in about a year after Atlas Venture and New Enterprise Associates backed a $29.4 million funding round for Synlogic, helping the company get rolling with a proprietary approach to synthetic biology. Using technology licensed from MIT’s Timothy Lu and Boston University’s Jim Collins, Synlogic is working to engineer microbes that can be tuned to have specific therapeutic effects, focusing first on rare diseases.
 
And Gutiérrez-Ramos brings a long track record of successful translational research, overseeing more than 25 projects in his time at Pfizer and heading up development work at GlaxoSmithKline and Millennium Pharmaceuticals prior to that.
 
Now, with a chief executive in place, Synlogic is moving on from its stealthy platform development and unveiling its pipeline. Tapping its microbe-engineering engine, the biotech is developing two preclinical candidates for urea cycle disorders, which result from enzyme deficiencies, and phenylketonuria, a rare ailment caused by a gene defect.
 
“Synlogic has assembled an outstanding team of founders, scientists, collaborators and investors to make the potential of synthetic biology a reality for the treatment of human disease,” Gutiérrez-Ramos said in a statement. “I am thrilled to lead them in this fascinating journey to change the world by bringing the future of medicine forward.”
 
By Damian Garde
 

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).